Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other neoplasm 1Breast 1

Conditions

Prostatic Neoplasms 8Metastatic Castration-resistant Prostate Cancer 2Prostatic Neoplasms, Castration-Resistant 1Prostate Adenocarcinoma 1Metastatic Castrate Resistant Prostate Cancer (mCRPC) 1Lymphatic Metastasis 1Hormone Refractory Prostate Cancer 1Carcinoma, Renal Cell 1Bone Metastatic Castration-resistant Prostate Cancer 1Anatomic Stage IV Breast Cancer AJCC v8 1

Interventions

Magnetic Resonance Spectroscopy 5Specimen Handling 4Biopsy 3Steroids 2Hormones 2Cyclin-Dependent Kinase Inhibitor p18 2Cyclin-Dependent Kinase Inhibitor p16 2trastuzumab deruxtecan 1trastuzumab biosimilar HLX02 1taxane 1radium Ra 223 dichloride 1pertuzumab 1naxitamab 1eicosapentaenoic acid ethyl ester 1eicosapentaenoic acid ethanolamide 1binimetinib 1abemaciclib 1X-Rays 1Trastuzumab 1Taxoids 1Taxes 1Radiotherapy 1Radiosurgery 1Radiation 1Photons 1Paclitaxel 1PF-05280014 1Ontruzant 1Ogivri 1Mastectomy, Simple 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Anatomic Stage IV Breast Cancer AJCC v8 × radium Ra 223 dichloride × 1 year × Clear all
NCT04090398 2026-05-13

Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy Treatment (Paclitaxel) for Advanced Breast Cancer That Has Spread to the Bones

National Cancer Institute (NCI)

Phase 2 Active not recruiting
70 enrolled
BreastOther neoplasm

Anatomic Stage IV Breast Cancer AJCC v8

Data powered by HemOnc (CC BY 4.0) Colophon âš¡